Promising data for candidate vaccines against Zika virus infection reported by Abbink et al. (1) on page 1129 of this issue raise hopes that one or more Zika virus vaccines may soon be ready for efficacy trials. Recent years have seen a barrage of emerging infectious diseases, including those caused by new pathogens such as Middle East respiratory syndrome (MERS) coronavirus, and those that are newly salient because of increased geographic spread, higher incidence, or genetic change, such as influenza A(H1N1)pdm09, Ebola virus, and Zika virus. Developing effective vaccines is a central goal for such pathogens.
Authors: Marc Lipsitch, Benjamin J. Cowling